NYMOX Provides Shareholder Update
September 10 2021 - 9:30AM
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is
pleased to provide an update on the Company's progress with its BPH
treatment product Fexapotide Triflutate.
The Company announced today that all Company
tasks have been completed and documented and that the upcoming
filing process in that regard has proceeded fully as planned. The
Company is satisfied that it has fulfilled all of its required
tasks and mandates at this point. The date of filing has been
extended in a minor way mainly due to the need for certain forms
and facility documents from third party vendors and contractors
that are routinely required. Management assures Nymox shareholders
that there are no material or unfamiliar elements unaccounted for
in this update.
Nymox is pleased to report that it has filed
with regulatory bodies for brand names for Fexapotide. The Company
has been formally informed by the authorities in more than one of
the major jurisdictions that the proposed marketing trade names
that were filed by the Company would be acceptable. Those
acceptances are always subject to the outcomes of the filing
processes.
Nymox is also pleased to report updates on the
acceptance and issuance of several new patents that will bolster
the intellectual property protections for the new drug. These are
from many different jurisdictions and provide increasing protection
for the Company's assets.
Dr Paul Averback, Nymox CEO said, "We are
extremely pleased with the results of our long-haul labors and we
expect to keep our supporters thoroughly informed, as much as we
can. We obviously cannot speak for third party collaborators with
whom we work except to say that we have nothing but good things to
say about the commitment to quality which exists with our vendors
and associates. The last few steps of documentation from the
outside are not under our control. However, we expect the filing to
occur soon and without major delay. The Company will report to
shareholders within 30 days with all the information at hand."
About Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation specializes in
the research and development of therapeutics and diagnostics, with
a particular emphasis on products targeted for the unmet needs of
the rapidly aging male population in developed economies. The
Company’s lead drug candidate for benign prostatic hyperplasia
(BPH), Fexapotide Triflutate (FT), has completed Phase 3
development in more than 70 clinical centers in the United States,
involving more than 1700 patients during the entire clinical
development program. Currently, the Company will soon be filing for
approval in major economies around the world, including the United
States and Europe.
For more information please contact
info@nymox.com or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Nymox, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements regarding the need for new options to
treat BPH and prostate cancer, the potential of Fexapotide to treat
BPH and prostate cancer and the estimated timing of further
developments for Fexapotide. Such forward-looking statements
involve substantial risks and uncertainties that could cause our
clinical development program, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the clinical drug development process, including the regulatory
approval process, the timing of Nymox's regulatory filings, Nymox's
substantial dependence on Fexapotide, Nymox's commercialization
plans and efforts and other matters that could affect the
availability or commercial potential of Fexapotide. Nymox
undertakes no obligation to update or revise any forward looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of Nymox in general, see Nymox's current
and future reports filed with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 20-F for the year
ended December 31, 2020, and its Quarterly Reports.
For Further Information
Contact:Randall
Lanham Nymox
Pharmaceutical Corporation1-800-93NYMOXwww.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Apr 2023 to Apr 2024